ATE458487T1 - Tumorbehandlung mit gliotoxin-derivaten - Google Patents

Tumorbehandlung mit gliotoxin-derivaten

Info

Publication number
ATE458487T1
ATE458487T1 AT06760774T AT06760774T ATE458487T1 AT E458487 T1 ATE458487 T1 AT E458487T1 AT 06760774 T AT06760774 T AT 06760774T AT 06760774 T AT06760774 T AT 06760774T AT E458487 T1 ATE458487 T1 AT E458487T1
Authority
AT
Austria
Prior art keywords
tumor treatment
gliotoxin
derivatives
gliotoxin derivatives
tumours
Prior art date
Application number
AT06760774T
Other languages
English (en)
Inventor
Rainer Hubmann
Wolfgang Sieghart
Original Assignee
Univ Wien Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med filed Critical Univ Wien Med
Application granted granted Critical
Publication of ATE458487T1 publication Critical patent/ATE458487T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT06760774T 2005-06-21 2006-06-21 Tumorbehandlung mit gliotoxin-derivaten ATE458487T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0104405A AT502055B1 (de) 2005-06-21 2005-06-21 Anti tumor medikament
PCT/AT2006/000253 WO2006135949A2 (en) 2005-06-21 2006-06-21 Tumour treatment with gliotoxin derivatives

Publications (1)

Publication Number Publication Date
ATE458487T1 true ATE458487T1 (de) 2010-03-15

Family

ID=37102560

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0104405A AT502055B1 (de) 2005-06-21 2005-06-21 Anti tumor medikament
AT06760774T ATE458487T1 (de) 2005-06-21 2006-06-21 Tumorbehandlung mit gliotoxin-derivaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0104405A AT502055B1 (de) 2005-06-21 2005-06-21 Anti tumor medikament

Country Status (7)

Country Link
US (1) US7981878B2 (de)
EP (1) EP1901750B1 (de)
AT (2) AT502055B1 (de)
AU (1) AU2006261566A1 (de)
CA (1) CA2612770A1 (de)
DE (1) DE602006012487D1 (de)
WO (1) WO2006135949A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120219568A1 (en) * 2011-02-24 2012-08-30 Zhejiang University Epidithiodioxopiprazines and uses thereof in treating cancer
US9442092B2 (en) 2011-06-20 2016-09-13 Kerry Lane Methods for treatment of autism
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
US9765090B2 (en) 2011-11-25 2017-09-19 Ewha University-Industry Collaboration Foundation Epidithiodioxopiperazine compound or its derivatives, and the use thereof
CA2880271C (en) 2012-08-13 2021-10-19 Genentech, Inc. Anti-jagged anitbodies and methods of use
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
HK1211963A1 (en) 2013-03-15 2016-06-03 豪夫迈．罗氏有限公司 Compositions and methods for diagnosis and treatment of hepatic cancers
EP2958926B1 (de) * 2013-05-24 2023-03-08 VASTHERA Co. Ltd. Epidithiodioxopiperazinverbindung oder derivate davon und verwendung davon
TR201810635T4 (tr) 2014-02-12 2018-08-27 Hoffmann La Roche Anti-jagged1 antikorları ve kullanım yöntemleri.
EP3282019A1 (de) 2016-08-09 2018-02-14 Medizinische Universität Wien Genotypisierung und behandlung von krebs, insbesondere chronischer lymphozytischer leukämie
KR102091730B1 (ko) * 2017-07-05 2020-03-23 바스테라 주식회사 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
EP4023224B1 (de) * 2019-08-28 2026-01-28 VASTHERA Co. Ltd. Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von soliden tumoren enthaltend ein epidithiodioxopiperazinderivat oder dessen pharmazeutisch verträgliche salze
CN116286897B (zh) * 2023-03-29 2024-05-03 佛山科学技术学院 一种编码酰基转移酶的Tri3基因及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
JPS61277617A (ja) 1985-05-31 1986-12-08 Yakult Honsha Co Ltd 坑血小板凝集剤
WO1992010198A1 (en) * 1990-12-06 1992-06-25 Johnson & Johnson Research Pty Limited Immunotherapeutic agents, compositions and methods
JP2801491B2 (ja) 1993-01-26 1998-09-21 敦 沼田 エピポリチオジオキソピペラジン誘導体およびその製造法
JP3498925B2 (ja) 1994-02-18 2004-02-23 日本肥糧株式会社 グリオクラディウム・ビレンスによるグリオトキシンの生産方法
KR19990082168A (ko) * 1996-12-02 1999-11-25 에가시라 구니오 글리오톡신 유도체 및 이를 함유하는 항암제
US6703221B1 (en) * 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
US20040101847A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
AU2003249382A1 (en) 2002-06-26 2004-01-19 Pharmablood Inc. A method and composition to elicit an effective autologous antitumoral immune response in a patient
EP1531825A2 (de) 2002-08-29 2005-05-25 University Of Southampton Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von leberkrankheiten

Also Published As

Publication number Publication date
WO2006135949A2 (en) 2006-12-28
US7981878B2 (en) 2011-07-19
AU2006261566A1 (en) 2006-12-28
US20090029974A1 (en) 2009-01-29
CA2612770A1 (en) 2006-12-28
AT502055B1 (de) 2007-11-15
DE602006012487D1 (de) 2010-04-08
EP1901750B1 (de) 2010-02-24
EP1901750A2 (de) 2008-03-26
AT502055A1 (de) 2007-01-15
WO2006135949A3 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
NL301089I2 (nl) imlifidase
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
LT3312197T (lt) Monokloniniai antikūnai prieš klaudiną 18, skirti vėžio gydymui
TW200738725A (en) Unsaturated mTOR inhibitors
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
EA200970738A1 (ru) Ингибиторы активности akt
WO2007013950A3 (en) Combination therapy of her expressing tumors
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2022007626A (es) Combinaciones.
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties